Agenus Announces Virtual Annual Shareholders Meeting
Agenus (NASDAQ: AGEN) has announced its Annual Shareholders Meeting set for June 8, 2022, at 3:30 p.m. ET, to be held virtually.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agenus (NASDAQ: AGEN) has announced its Annual Shareholders Meeting set for June 8, 2022, at 3:30 p.m. ET, to be held virtually. Shareholders can register from 3:15 p.m. ET via a control number found in proxy materials. The meeting will be accessible in listen-only mode for non-shareholders. Agenus focuses on immuno-oncology, developing therapies that engage the immune system against cancer and infections, utilizing a range of advanced platforms and facilities.
Positive
- The Annual Shareholders Meeting provides transparency and engagement opportunities for investors.
- Agenus's focus on broadening patient access to cancer immunotherapy highlights its commitment to innovative treatments.
Negative
- None.
Details
News Market Reaction – AGEN
The recorded move for AGEN in the trading session of this news was +0.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that its Annual Shareholders Meeting will begin at 3:30 p.m. ET on June 8, 2022 and will be conducted in a virtual format only. Registration for attendees will start at 3:15 p.m. ET.
To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2022 and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests.
Webcast Information:
Date: Wednesday, June 8, 2022
Time: 3:30 p.m. ET
A live webcast and replay will be accessible from the Company's website at https://investor.agenusbio.com/events-and-presentations and at www.virtualshareholdermeeting.com/AGEN2022.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
Contact
Ethan Lovell
Chief External Affairs & Communications, Agenus
339-927-1763
ethan.lovell@agenusbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.